http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 10 Sep 2026 07:15:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Cerenome+Announces+Up+to+%2420+Million+Financing+Facility+with+Royalty-Based+Repayment/27045073.html <p align="center"><em>Capital will support continued CNSide® commercial scale-up and development</em></p> <p align="center"><em>Initial tranche of funding provided at closing with future tranches linked to milestones</em></p> <p align="center"><em>Forecasted cash runway now into 2028</em></p> <p align="justify">HOUSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform of precision diagnostics, targeted therapeutics, and artificial intelligence, today announced that it has entered into a financing agreement with 3i, LP (“3i Fund”) for a senior secured facility of up to $20 million with royalty-based repayments. Under the agreement, the http://www.streetinsider.com/Press+Releases/Cerenome+Announces+Up+to+%2420+Million+Financing+Facility+with+Royalty-Based+Repayment/27045073.html Thu, 10 Sep 2026 07:15:00 -0400 CNSY PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Announces+Up+to+%2420+Million+Financing+Facility+with+Royalty-Based+Repayment/27045073.html <p align="center"><em>Capital will support continued CNSide® commercial scale-up and development</em></p> <p align="center"><em>Initial tranche of funding provided at closing with future tranches linked to milestones</em></p> <p align="center"><em>Forecasted cash runway now into 2028</em></p> <p align="justify">HOUSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform of precision diagnostics, targeted therapeutics, and artificial intelligence, today announced that it has entered into a financing agreement with 3i, LP (“3i Fund”) for a senior secured facility of up to $20 million with royalty-based repayments. Under the agreement, the http://www.streetinsider.com/Press+Releases/Cerenome+Announces+Up+to+%2420+Million+Financing+Facility+with+Royalty-Based+Repayment/27045073.html Thu, 10 Sep 2026 07:15:00 -0400 CNSY PSTV http://www.streetinsider.com/Globe+Newswire/Cerenome+Announces+Up+to+%2420+Million+Financing+Facility+with+Royalty-Based+Repayment/27045073.html <p align="center"><em>Capital will support continued CNSide® commercial scale-up and development</em></p> <p align="center"><em>Initial tranche of funding provided at closing with future tranches linked to milestones</em></p> <p align="center"><em>Forecasted cash runway now into 2028</em></p> <p align="justify">HOUSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform of precision diagnostics, targeted therapeutics, and artificial intelligence, today announced that it has entered into a financing agreement with 3i, LP (“3i Fund”) for a senior secured facility of up to $20 million with royalty-based repayments. Under the agreement, the http://www.streetinsider.com/Globe+Newswire/Cerenome+Announces+Up+to+%2420+Million+Financing+Facility+with+Royalty-Based+Repayment/27045073.html Thu, 10 Sep 2026 07:15:00 -0400 CNSY PSTV http://www.streetinsider.com/Globe+Newswire/Cerenome+Announces+Up+to+%2420+Million+Financing+Facility+with+Royalty-Based+Repayment/27045073.html <p align="center"><em>Capital will support continued CNSide® commercial scale-up and development</em></p> <p align="center"><em>Initial tranche of funding provided at closing with future tranches linked to milestones</em></p> <p align="center"><em>Forecasted cash runway now into 2028</em></p> <p align="justify">HOUSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform of precision diagnostics, targeted therapeutics, and artificial intelligence, today announced that it has entered into a financing agreement with 3i, LP (“3i Fund”) for a senior secured facility of up to $20 million with royalty-based repayments. Under the agreement, the http://www.streetinsider.com/Globe+Newswire/Cerenome+Announces+Up+to+%2420+Million+Financing+Facility+with+Royalty-Based+Repayment/27045073.html Thu, 10 Sep 2026 07:15:00 -0400 CNSY PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html <p align="center"><em>Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial shows strong safety signal </em>  </p> <p align="center"><em>CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs</em></p> <p align="justify">HOUSTON, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <strong>Cerenome,</strong> <strong>Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”)</strong> today highlights data from two scientific posters presented at the 2026 Society for Neuro-Oncology/American Society of Clinical Oncology (SNO/ASCO) CNS Metastases Conference, held August 13–15 in Boston. One presentation featured updated pharmacokinetic (PK), http://www.streetinsider.com/Press+Releases/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html Thu, 20 Aug 2026 07:30:00 -0400 A.27043835 CNSY O.00066617 O.20202125 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html <p align="center"><em>Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial shows strong safety signal </em>  </p> <p align="center"><em>CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs</em></p> <p align="justify">HOUSTON, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <strong>Cerenome,</strong> <strong>Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”)</strong> today highlights data from two scientific posters presented at the 2026 Society for Neuro-Oncology/American Society of Clinical Oncology (SNO/ASCO) CNS Metastases Conference, held August 13–15 in Boston. One presentation featured updated pharmacokinetic (PK), http://www.streetinsider.com/Press+Releases/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html Thu, 20 Aug 2026 07:30:00 -0400 A.27043835 CNSY O.00066617 O.20202125 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html <p align="center"><em>Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial shows strong safety signal </em>  </p> <p align="center"><em>CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs</em></p> <p align="justify">HOUSTON, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <strong>Cerenome,</strong> <strong>Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”)</strong> today highlights data from two scientific posters presented at the 2026 Society for Neuro-Oncology/American Society of Clinical Oncology (SNO/ASCO) CNS Metastases Conference, held August 13–15 in Boston. One presentation featured updated pharmacokinetic (PK), http://www.streetinsider.com/Press+Releases/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html Thu, 20 Aug 2026 07:30:00 -0400 A.27043835 CNSY O.00066617 O.20202125 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html <p align="center"><em>Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial shows strong safety signal </em>  </p> <p align="center"><em>CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs</em></p> <p align="justify">HOUSTON, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <strong>Cerenome,</strong> <strong>Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”)</strong> today highlights data from two scientific posters presented at the 2026 Society for Neuro-Oncology/American Society of Clinical Oncology (SNO/ASCO) CNS Metastases Conference, held August 13–15 in Boston. One presentation featured updated pharmacokinetic (PK), http://www.streetinsider.com/Press+Releases/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html Thu, 20 Aug 2026 07:30:00 -0400 A.27043835 CNSY O.00066617 O.20202125 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html <p align="center"><em>Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial shows strong safety signal </em>  </p> <p align="center"><em>CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs</em></p> <p align="justify">HOUSTON, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <strong>Cerenome,</strong> <strong>Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”)</strong> today highlights data from two scientific posters presented at the 2026 Society for Neuro-Oncology/American Society of Clinical Oncology (SNO/ASCO) CNS Metastases Conference, held August 13–15 in Boston. One presentation featured updated pharmacokinetic (PK), http://www.streetinsider.com/Press+Releases/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html Thu, 20 Aug 2026 07:30:00 -0400 A.27043835 CNSY O.00066617 O.20202125 PSTV http://www.streetinsider.com/Globe+Newswire/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html <p align="center"><em>Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial shows strong safety signal </em>  </p> <p align="center"><em>CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs</em></p> <p align="justify">HOUSTON, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <strong>Cerenome,</strong> <strong>Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”)</strong> today highlights data from two scientific posters presented at the 2026 Society for Neuro-Oncology/American Society of Clinical Oncology (SNO/ASCO) CNS Metastases Conference, held August 13–15 in Boston. One presentation featured updated pharmacokinetic (PK), http://www.streetinsider.com/Globe+Newswire/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html Thu, 20 Aug 2026 07:30:00 -0400 A.27043835 CNSY O.00066617 O.20202125 PSTV http://www.streetinsider.com/Globe+Newswire/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html <p align="center"><em>Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial shows strong safety signal </em>  </p> <p align="center"><em>CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs</em></p> <p align="justify">HOUSTON, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <strong>Cerenome,</strong> <strong>Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”)</strong> today highlights data from two scientific posters presented at the 2026 Society for Neuro-Oncology/American Society of Clinical Oncology (SNO/ASCO) CNS Metastases Conference, held August 13–15 in Boston. One presentation featured updated pharmacokinetic (PK), http://www.streetinsider.com/Globe+Newswire/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html Thu, 20 Aug 2026 07:30:00 -0400 A.27043835 CNSY O.00066617 O.20202125 PSTV http://www.streetinsider.com/Globe+Newswire/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html <p align="center"><em>Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial shows strong safety signal </em>  </p> <p align="center"><em>CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs</em></p> <p align="justify">HOUSTON, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <strong>Cerenome,</strong> <strong>Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”)</strong> today highlights data from two scientific posters presented at the 2026 Society for Neuro-Oncology/American Society of Clinical Oncology (SNO/ASCO) CNS Metastases Conference, held August 13–15 in Boston. One presentation featured updated pharmacokinetic (PK), http://www.streetinsider.com/Globe+Newswire/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html Thu, 20 Aug 2026 07:30:00 -0400 A.27043835 CNSY O.00066617 O.20202125 PSTV http://www.streetinsider.com/Globe+Newswire/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html <p align="center"><em>Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial shows strong safety signal </em>  </p> <p align="center"><em>CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs</em></p> <p align="justify">HOUSTON, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <strong>Cerenome,</strong> <strong>Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”)</strong> today highlights data from two scientific posters presented at the 2026 Society for Neuro-Oncology/American Society of Clinical Oncology (SNO/ASCO) CNS Metastases Conference, held August 13–15 in Boston. One presentation featured updated pharmacokinetic (PK), http://www.streetinsider.com/Globe+Newswire/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html Thu, 20 Aug 2026 07:30:00 -0400 A.27043835 CNSY O.00066617 O.20202125 PSTV http://www.streetinsider.com/Globe+Newswire/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html <p align="center"><em>Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial shows strong safety signal </em>  </p> <p align="center"><em>CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs</em></p> <p align="justify">HOUSTON, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <strong>Cerenome,</strong> <strong>Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”)</strong> today highlights data from two scientific posters presented at the 2026 Society for Neuro-Oncology/American Society of Clinical Oncology (SNO/ASCO) CNS Metastases Conference, held August 13–15 in Boston. One presentation featured updated pharmacokinetic (PK), http://www.streetinsider.com/Globe+Newswire/Cerenome+Highlights+Presentations+at+the+2026+SNOASCO+CNS+Metastases+Conference+Demonstrating+Progress+in+Both+Therapeutics+and+Diagnostics+Business+Lines/26952869.html Thu, 20 Aug 2026 07:30:00 -0400 A.27043835 CNSY O.00066617 O.20202125 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV